125 related articles for article (PubMed ID: 22792751)
1. [Current conceptions of neurocytoprotective therapy].
Gomazkov OA; Afanas'ev VV; Rumiantseva SA; Stupin VA; Silina EV; Sokhova OA
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12 Pt 2):58-63. PubMed ID: 22792751
[TBL] [Abstract][Full Text] [Related]
2. [Neuroprotective treatment of chronic cerebrovascular insufficiency].
Anisimova AV; Kolesnikova TI; Iutskova EV; Galkin SS
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(7):30-2. PubMed ID: 25176263
[TBL] [Abstract][Full Text] [Related]
3. Cerebrolysin in Alzheimer's disease.
Antón Álvarez X; Fuentes P
Drugs Today (Barc); 2011 Jul; 47(7):487-513. PubMed ID: 22013558
[TBL] [Abstract][Full Text] [Related]
4. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia.
Allegri RF; Guekht A
Drugs Today (Barc); 2012 Apr; 48 Suppl A():25-41. PubMed ID: 22514793
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window.
Schauer E; Wronski R; Patockova J; Moessler H; Doppler E; Hutter-Paier B; Windisch M
J Neural Transm (Vienna); 2006 Jul; 113(7):855-68. PubMed ID: 16362636
[TBL] [Abstract][Full Text] [Related]
6. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders.
Masliah E; Díez-Tejedor E
Drugs Today (Barc); 2012 Apr; 48 Suppl A():3-24. PubMed ID: 22514792
[TBL] [Abstract][Full Text] [Related]
7. [The influence of cerebrolysin on the efficiency of subsequent therapy with amiridine++ in Alzheimer's disease patients (neuropsychological investigation)].
Roshchina IF; Kolykhalov IV; Selezneva ND; Zharikov GA; Gerasimov NP; Gavrilova SI
Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(12):43-6. PubMed ID: 10629930
[TBL] [Abstract][Full Text] [Related]
8. [The effect of cerebrolysin on moderate cognitive impairment in cerebral vascular insufficiency (a clinical and electrophysiological study)].
Damulin IV; Koberskaia NN; Mkhitarian EA
Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(5):32-8. PubMed ID: 18379494
[TBL] [Abstract][Full Text] [Related]
9. [The therapeutic potential of cerebrolysin in the preventive therapy of Alzheimer's disease].
Gavrilova SI; Fedorova IaB; Kolykhalov IV; Odinak MM; Emelin AIu; Kashin AV; Selezneva ND; Kalyn IaB; Roshchina IF
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(8):24-8. PubMed ID: 18833104
[TBL] [Abstract][Full Text] [Related]
10. Natural products from marine organisms with neuroprotective activity in the experimental models of Alzheimer's disease, Parkinson's disease and ischemic brain stroke: their molecular targets and action mechanisms.
Choi DY; Choi H
Arch Pharm Res; 2015 Feb; 38(2):139-70. PubMed ID: 25348867
[TBL] [Abstract][Full Text] [Related]
11. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.
Alvarez XA; Cacabelos R; Laredo M; Couceiro V; Sampedro C; Varela M; Corzo L; Fernandez-Novoa L; Vargas M; Aleixandre M; Linares C; Granizo E; Muresanu D; Moessler H
Eur J Neurol; 2006 Jan; 13(1):43-54. PubMed ID: 16420392
[TBL] [Abstract][Full Text] [Related]
12. [4th International Symposium. "Cerebrolysin: pharmacological effects and role in clinical practice"].
Gomazkov OA
Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):69-70. PubMed ID: 12378888
[No Abstract] [Full Text] [Related]
13. [An impact of neuroprotective therapy on blood rheological and morphodensitometric parameters in patients with chronic cerebral ischemia].
Anisimova AV; Kolesnikova TI; Iutskova EV; Galkin SS; Zimin IA
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(10):72-80. PubMed ID: 25591521
[TBL] [Abstract][Full Text] [Related]
14. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.
Gauthier S; Proaño JV; Jia J; Froelich L; Vester JC; Doppler E
Dement Geriatr Cogn Disord; 2015; 39(5-6):332-47. PubMed ID: 25832905
[TBL] [Abstract][Full Text] [Related]
15. Hope Dies Last-Evidence Again Fails to Support a Neuroprotectant: Cerebrolysin for Acute Ischemic Stroke.
Bereczki D
Stroke; 2017 Sep; 48(9):2343-2344. PubMed ID: 28747461
[No Abstract] [Full Text] [Related]
16. Alzheimer's disease: cerebrolysin and nanotechnology as a therapeutic strategy.
Sharma HS; Muresanu DF; Sharma A
Neurodegener Dis Manag; 2016 Dec; 6(6):453-456. PubMed ID: 27827552
[No Abstract] [Full Text] [Related]
17. [A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke].
Skvortsova VI; Stakhovskaia LV; Gubskiĭ LV; Shamalov NA; Tikhonova IV; Smychkov AS
Zh Nevrol Psikhiatr Im S S Korsakova; 2004; (Suppl 11):51-5. PubMed ID: 15559222
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological approaches to the therapy of Alzheimer's disease].
Gavrilova SI
Vestn Ross Akad Med Nauk; 2006; (9-10):30-4. PubMed ID: 17111921
[TBL] [Abstract][Full Text] [Related]
19. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.
Lang W; Stadler CH; Poljakovic Z; Fleet D;
Int J Stroke; 2013 Feb; 8(2):95-104. PubMed ID: 23009193
[TBL] [Abstract][Full Text] [Related]
20. [Comparative analysis of efficacy of certain neuroprotectors in ischemic stroke].
Skorokhodov AP; Dudina AA; Kolesnikova EA; Koron AE; Kobantsev IuA; Sedova AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Suppl 17():52-6. PubMed ID: 18193579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
